| Literature DB >> 33490121 |
Elsa P Bianchini1, Claire Auditeau1, Mahita Razanakolona1, Marc Vasse1,2, Delphine Borgel1,3.
Abstract
Bleeding and thrombotic disorders result from imbalances in coagulation or fibrinolysis, respectively. Inhibitors from the serine protease inhibitor (serpin) family have a key role in regulating these physiological events, and thus stand out as potential therapeutic targets for modulating fibrin clot formation or dismantling. Here, we review the diversity of serpin-targeting strategies in the area of hemostasis, and detail the suggested use of modified serpins and serpin inhibitors (ranging from small-molecule drugs to antibodies) to treat or prevent bleeding or thrombosis.Entities:
Keywords: antithrombin (AT); plasminogen activator inhibitor 1 (PAI-1); protease nexin I (PN-1); protein Z-dependent protease inhibitor (ZPI); serpin (serine proteinase inhibitor); therapy
Year: 2021 PMID: 33490121 PMCID: PMC7817699 DOI: 10.3389/fcvm.2020.622778
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X